In this issue:
Enzalutamide for biochemically recurrent prostate cancer
Metastasis-directed therapy for oligometastatic prostate cancer
Outcomes with PSA persistence after radical prostatectomy
Tumour-based epigenetic signatures of prostate cancer aggressiveness
68Gallium-PSMA-PET in pelvic node-positive prostate cancer after RT
Validation of the Decipher genomic classifier in early localised prostate cancer
Moderately hypofractionated radiotherapy for intermediate-risk prostate cancer
PSA response to predict progression in mHSPC
Utility of MRI perilesional biopsy in prostate cancer
5α-reductase inhibitors and mpMRI characteristics and prostate cancer detection
Please login below to download this issue (PDF)